Cytosorbents (CTSO) Cash & Equivalents (2010 - 2026)

Cytosorbents' Cash & Equivalents history runs 17 years deep, the most recent figure standing at $4.8 million for Q1 2026.

• Quarterly Cash & Equivalents fell 63.39% year-over-year to $4.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.8 million (down 63.39% YoY) and the FY2025 annual result came in at $6.2 million, down 36.0% from the prior year.
• Cash & Equivalents was $4.8 million for Q1 2026 at Cytosorbents, down from $6.2 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $43.0 million in Q1 2022 and bottomed at $4.8 million in Q1 2026.
• A 5-year average of $14.6 million and a median of $10.2 million in 2025 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2025 — Cash & Equivalents soared 52.29% — and 2026, when it slumped 63.39%.
• Cytosorbents' Cash & Equivalents stood at $22.1 million in 2022, then plunged by 36.19% to $14.1 million in 2023, then tumbled by 30.9% to $9.8 million in 2024, then plunged by 36.0% to $6.2 million in 2025, then slipped by 23.19% to $4.8 million in 2026.
• Business Quant data shows CTSO's Cash & Equivalents at $4.8 million in Q1 2026, $6.2 million in Q4 2025, and $7.5 million in Q3 2025.